Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt repayments

Ratios

Tango Therapeutics (TNGX) Shares Issued (2020 - 2026)

Tango Therapeutics has reported Shares Issued over the past 5 years, most recently at $41.7 million for Q1 2024.

For Q1 2024, Shares Issued rose 57054.79% year-over-year to $41.7 million; the TTM value through Sep 2024 reached $41.8 million, changed N/A, while the annual FY2023 figure was $689000.0, N/A changed from the prior year.
Shares Issued for Q1 2024 was $41.7 million at Tango Therapeutics, up from $73000.0 in the prior quarter.
Over five years, Shares Issued peaked at $166.8 million in Q4 2020 and troughed at $25000.0 in Q2 2020.
A 5-year average of $26.8 million and a median of $352000.0 in 2021 define the central range for Shares Issued.
Biggest five-year swings in Shares Issued: tumbled 99.94% in 2021 and later surged 57054.79% in 2024.
Year by year, Shares Issued stood at $166.8 million in 2020, then tumbled by 99.94% to $101000.0 in 2021, then soared by 162.38% to $265000.0 in 2022, then tumbled by 72.45% to $73000.0 in 2023, then surged by 57054.79% to $41.7 million in 2024.
Business Quant data shows Shares Issued for TNGX at $41.7 million in Q1 2024, $73000.0 in Q1 2023, and $265000.0 in Q1 2022.